Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 7/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.30 |
| ▸ | CCNC | P24863 | 1/20 | 0.30 |
| ▸ | CDK8 | P49336 | 1/20 | 0.30 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.30 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776038 | 0.82 | CNR1 (0.36) | ABL1MAP4K1 | |
| SCHEMBL16776013 | 0.82 | FGFR4 (0.44) | WNT3ARPS6KA3FGFR4MAPK1GRM5 | |
| SCHEMBL16776016 | 0.81 | WNT3A (0.40) | ABL1CYP11B2WNT3AMAPK1GRM5 | |
| SCHEMBL16776204 | 0.81 | DYRK1A (0.34) | ABL1CYP11B2AKT1CYP3A4 | |
| SCHEMBL16776226 | 0.81 | HTR2C (0.45) | ABL1RPS6KA3CYP3A4 | |
| SCHEMBL16776211 | 0.81 | RPS6KA3 (0.43) | ABL1CYP11B2WNT3ARPS6KA3MAPK1 | |
| SCHEMBL16776025 | 0.79 | CYP11B2 (0.38) | CYP11B2WNT3AAKT1MAPK1PSEN1 | |
| SCHEMBL16776227 | 0.79 | FGFR4 (0.37) | ABL1WNT3AFGFR4MAPK1 | |
| SCHEMBL16776229 | 0.78 | CYP11B2 (0.37) | ABL1CYP11B2WNT3AFGFR4MAPK1 | |
| SCHEMBL16776424 | 0.77 | DYRK1A (0.40) | ABL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ABL1 4089/4885CYP11B2 1166/4885WNT3A 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.